Patent cliff fears drive through 2020’s second largest pharma deal
Despite an M&A slowdown amid coronavirus uncertainties, Alexion Pharmaceuticals has splashed out more than $1 billion in the face of imminent threats to its IP position in the US and Europe
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.